Tandem Other Stockholder Equity vs Common Stock Shares Outstanding Analysis
TNDM Stock | USD 47.23 0.07 0.15% |
Tandem Diabetes financial indicator trend analysis is much more than just breaking down Tandem Diabetes Care prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tandem Diabetes Care is a good investment. Please check the relationship between Tandem Diabetes Other Stockholder Equity and its Common Stock Shares Outstanding accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Other Stockholder Equity vs Common Stock Shares Outstanding
Other Stockholder Equity vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tandem Diabetes Care Other Stockholder Equity account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Tandem Diabetes' Other Stockholder Equity and Common Stock Shares Outstanding is 0.9. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Tandem Diabetes Care, assuming nothing else is changed. The correlation between historical values of Tandem Diabetes' Other Stockholder Equity and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Tandem Diabetes Care are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Other Stockholder Equity i.e., Tandem Diabetes' Other Stockholder Equity and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.9 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Other Stockholder Equity
Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Tandem Diabetes' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tandem Diabetes Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Tandem Diabetes' Selling General Administrative is very stable compared to the past year. As of the 20th of May 2024, Tax Provision is likely to grow to about 2.5 M, while Enterprise Value Over EBITDA is likely to drop (20.24).
2021 | 2023 | 2024 (projected) | Interest Expense | 4.3M | 7.6M | 5.8M | Depreciation And Amortization | 13.8M | 15.7M | 9.4M |
Tandem Diabetes fundamental ratios Correlations
Click cells to compare fundamentals
Tandem Diabetes Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Tandem Diabetes fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Other Current Liab | 71.5M | 70.5M | 84.4M | 77.6M | 84.6M | 88.8M | |
Total Current Liabilities | 99.4M | 103.9M | 131.9M | 165.3M | 195.3M | 205.0M | |
Total Stockholder Equity | 195.0M | 366.3M | 433.1M | 439.9M | 313.6M | 160.8M | |
Other Liab | 17.7M | 27.4M | 34.8M | 36.1M | 41.5M | 43.6M | |
Property Plant And Equipment Net | 48.5M | 69.8M | 77.9M | 179.2M | 164.3M | 172.5M | |
Net Debt | (30.8M) | 133.7M | 243.5M | 247.4M | 356.8M | 374.6M | |
Retained Earnings | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (951.8M) | (904.2M) | |
Accounts Payable | 17.7M | 17.8M | 28.0M | 55.7M | 49.6M | 52.1M | |
Cash | 51.2M | 94.6M | 71.2M | 172.5M | 58.9M | 65.4M | |
Non Current Assets Total | 50.0M | 79.2M | 93.6M | 202.8M | 204.7M | 214.9M | |
Non Currrent Assets Other | 708K | 580K | 9.1M | 19.0M | 37.6M | 39.4M | |
Other Assets | 708K | 29.2M | 9.1M | 10.7M | 12.3M | 12.9M | |
Cash And Short Term Investments | 176.5M | 484.9M | 623.8M | 616.9M | 467.9M | 242.0M | |
Net Receivables | 46.6M | 82.2M | 110.7M | 114.7M | 105.6M | 110.8M | |
Common Stock Total Equity | 59K | 14.3M | 64K | 65K | 74.8K | 71.0K | |
Common Stock Shares Outstanding | 58.5M | 61.0M | 64.3M | 64.1M | 65.0M | 68.2M | |
Short Term Investments | 125.3M | 390.3M | 552.6M | 444.4M | 409.0M | 429.5M | |
Liabilities And Stockholders Equity | 326.1M | 716.4M | 905.1M | 1.1B | 952.7M | 1.0B | |
Non Current Liabilities Total | 31.7M | 246.3M | 340.2M | 447.5M | 443.8M | 466.0M | |
Inventory | 49.1M | 63.7M | 68.6M | 111.1M | 157.9M | 165.8M | |
Other Current Assets | 4.0M | 6.4M | 8.4M | 7.2M | 16.6M | 17.4M | |
Other Stockholder Equity | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 669.8M | |
Total Liab | 131.1M | 350.1M | 472.0M | 612.8M | 639.0M | 671.0M | |
Property Plant And Equipment Gross | 48.5M | 50.0M | 77.9M | 179.2M | 217.1M | 228.0M | |
Total Current Assets | 276.1M | 637.2M | 811.5M | 850.0M | 748.0M | 785.4M | |
Accumulated Other Comprehensive Income | 122K | 220K | (616K) | (1.8M) | 1.4M | 1.4M | |
Common Stock | 59K | 62K | 64K | 65K | 66K | 41.6K | |
Property Plant Equipment | 32.9M | 50.0M | 50.4M | 68.6M | 78.8M | 82.8M | |
Current Deferred Revenue | 3.9M | 6.1M | 10.2M | 18.8M | 44.0M | 46.2M | |
Intangible Assets | 777K | 8.8M | 6.6M | 4.6M | 2.8M | 3.5M | |
Net Tangible Assets | 195.0M | 366.3M | 433.1M | 439.9M | 505.9M | 531.2M | |
Retained Earnings Total Equity | (624.8M) | (659.2M) | (634.6M) | (729.2M) | (656.3M) | (689.1M) | |
Capital Surpluse | 819.6M | 1.0B | 1.1B | 1.2B | 1.3B | 776.1M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Tandem Diabetes Care using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (2.16) | Revenue Per Share 11.817 | Quarterly Revenue Growth 0.132 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.